Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Intrinsic Value
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. [ Read More ]
The intrinsic value of one ADAP stock under the Base Case scenario is 3.4 USD. Compared to the current market price of 1.58 USD, Adaptimmune Therapeutics PLC is Undervalued by 54%.
Valuation Backtest
Adaptimmune Therapeutics PLC
Run backtest to discover the historical profit from buying and selling ADAP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Adaptimmune Poised for Near-Term Growth
2023-Q4 Earnings Call
In 2023, Adaptimmune transitioned through corporate restructuring and completed a merger with TCR² Therapeutics, laying the groundwork for commercial success in 2024 and beyond. The company submitted the Biologics License Application (BLA) for afami-cel, marking a pivotal milestone as the first engineered T-cell therapy for solid tumors. With the FDA currently reviewing afami-cel, Adaptimmune expects to launch with initial availability planned for Q4 2024, aiming for 600 to 700 patient treatments annually. Financial stability is foreseen, with $147 million in liquidity and anticipated payments from Genentech to fund operations into early 2026. Adaptimmune projects up to $400 million in peak sales from its sarcoma franchise, including the recovered lete-cel therapy.
Balance Sheet Decomposition
Adaptimmune Therapeutics PLC
Current Assets | 207.6m |
Cash & Short-Term Investments | 146.9m |
Receivables | 46.9m |
Other Current Assets | 13.7m |
Non-Current Assets | 75.1m |
PP&E | 71.7m |
Intangibles | 330k |
Other Non-Current Assets | 3m |
Current Liabilities | 72.8m |
Accounts Payable | 8.1m |
Accrued Liabilities | 35.6m |
Other Current Liabilities | 29m |
Non-Current Liabilities | 170.3m |
Other Non-Current Liabilities | 170.3m |
Earnings Waterfall
Adaptimmune Therapeutics PLC
Revenue
|
60.3m
USD
|
Operating Expenses
|
-191m
USD
|
Operating Income
|
-130.7m
USD
|
Other Expenses
|
16.8m
USD
|
Net Income
|
-113.9m
USD
|
Free Cash Flow Analysis
Adaptimmune Therapeutics PLC
What is Free Cash Flow?
ADAP Profitability Score
Profitability Due Diligence
Adaptimmune Therapeutics PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Adaptimmune Therapeutics PLC's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
ADAP Solvency Score
Solvency Due Diligence
Adaptimmune Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Adaptimmune Therapeutics PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADAP Price Targets Summary
Adaptimmune Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for ADAP is 3.84 USD with a low forecast of 1.01 USD and a high forecast of 9.45 USD.
Ownership
ADAP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ADAP Price
Adaptimmune Therapeutics PLC
Average Annual Return | 57.42% |
Standard Deviation of Annual Returns | 224.06% |
Max Drawdown | -96% |
Market Capitalization | 390m USD |
Shares Outstanding | 246 824 992 |
Percentage of Shares Shorted | 2.6% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 494 full-time employees. The company went IPO on 2015-05-06. The Company’s Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. The Company’s clinical trials include SPEARHEAD-1 Phase II Trial with afamitresgene autoleucel (afami-cel), SPEARHEAD-2 Phase II trial with afami-cel, SURPASS Phase I trial with ADP-A2M4CD8, ADP-A2AFP Phase I trial and Afami-cel Phase I trial radiation sub-study.
Contact
IPO
Employees
Officers
The intrinsic value of one ADAP stock under the Base Case scenario is 3.4 USD.
Compared to the current market price of 1.58 USD, Adaptimmune Therapeutics PLC is Undervalued by 54%.